8-K: Hinge Health Soars with 55% Revenue Growth in Q2

Hinge Health, Inc. announced strong second quarter 2025 financial results, driven by 55% year-over-year revenue growth and a significant shift to non-GAAP operating profitability.

Summary

• Revenue for the second quarter ended June 30, 2025, increased 55% year-over-year to $139.1 million, up from $89.8 million in Q2 2024.
• Non-GAAP income from operations reached $26.1 million in Q2 2025, a significant improvement from a non-GAAP loss of $14.4 million in Q2 2024.
• GAAP loss from operations was $580.7 million, which included $591.0 million in stock-based compensation expense.
• Net cash provided by operating activities increased to $20.2 million in Q2 2025 from $14.9 million in Q2 2024.
• Free cash flow was $32.6 million, up from $14.0 million in Q2 2024.
• The company's cash, cash equivalents, marketable securities, and restricted cash stood at $415.1 million as of June 30, 2025.
• Last Twelve Months (LTM) calculated billings grew 55% to $568.4 million.
• The number of clients increased 32% to 2,359 compared to 1,785 clients in Q2 2024.
• Hinge Health expects Q3 2025 revenue between $141 million and $143 million, and non-GAAP income from operations between $17 million and $21 million.
• For Fiscal Year 2025, revenue is projected to be between $548 million and $552 million, with non-GAAP income from operations between $77 million and $83 million.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to exceptional revenue growth, a significant turnaround to non-GAAP operating profitability, strong free cash flow generation, and optimistic future guidance. While a large GAAP loss exists, it is primarily due to non-cash stock-based compensation, which is common for high-growth tech companies and is offset by strong non-GAAP performance.

Positives

• Achieved 55% year-over-year revenue growth in Q2 2025, reaching $139.1 million.
• Transitioned to non-GAAP operating income of $26.1 million in Q2 2025, a significant improvement from a loss in the prior year.
• Generated strong free cash flow of $32.6 million in Q2 2025, more than double the $14.0 million from Q2 2024.
• Increased net cash provided by operating activities to $20.2 million.
• Expanded client base by 32% year-over-year, reaching 2,359 clients.
• Provided positive financial guidance for Q3 and full year 2025, projecting continued revenue growth and non-GAAP operating profitability.

Negatives

• GAAP gross margin decreased to 70% in Q2 2025 from 74% in Q2 2024.
• Reported a substantial GAAP loss from operations of $580.7 million, primarily due to $591.0 million in stock-based compensation expense.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from projections.
• Specific risk factors are more fully described in the company's Prospectus dated May 21, 2025, filed with the SEC on May 22, 2025, and in other SEC filings, including the upcoming Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025.

Future Outlook

Hinge Health projects Q3 2025 revenue to be between $141 million and $143 million, reflecting 41% year-over-year growth at the midpoint, with non-GAAP income from operations expected between $17 million and $21 million. For the full fiscal year 2025, the company anticipates revenue between $548 million and $552 million, also representing 41% year-over-year growth at the midpoint, and non-GAAP income from operations between $77 million and $83 million.

Management Comments

• Daniel Perez, Co-Founder and CEO, stated: "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform."
• Daniel Perez also commented: "The journey of automating healthcare delivery will be challenging, but were excited about our momentum and are moving with haste to capture this opportunity."

Industry Context

Hinge Health operates in the rapidly evolving digital health sector, specifically targeting musculoskeletal conditions with an AI-powered care model. The strong revenue growth and shift to non-GAAP operating profitability suggest the company is effectively capturing market share and demonstrating the scalability of its technology-driven healthcare delivery model, aligning with broader industry trends towards virtual care and AI integration for cost reduction and improved patient outcomes.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard assessment. However, the 55% year-over-year revenue growth and positive free cash flow generation are indicative of strong performance within the digital health space, which often prioritizes growth and path to profitability.

Stakeholder Impact

• Shareholders: Positive financial results and outlook could lead to increased investor confidence and potential share price appreciation.
• Customers (Clients): Continued growth in client numbers suggests strong adoption and satisfaction with Hinge Health's AI-powered platform.
• Employees: The significant stock-based compensation expense indicates a substantial equity component in employee compensation, potentially impacting employee retention and motivation. The prior strategic shift away from kits suggests ongoing adaptation in operations.

Next Steps

• Host a conference call and webcast for investors on August 5, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial results, business highlights, and financial outlook.
• File the Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, with the SEC on or around August 11, 2025.
• Continue to monitor the company's investor relations website (ir.hingehealth.com) for material non-public information, upcoming investor conferences, and Regulation FD compliance.

Key Dates

Recommendation

Hinge Health's Q2 2025 results demonstrate exceptional operational momentum, marked by 55% year-over-year revenue growth and a pivotal shift to non-GAAP operating profitability. The robust free cash flow generation and significant client expansion underscore the effectiveness of its AI-powered platform in the digital health market. While the GAAP loss is substantial, it is largely attributable to non-cash stock-based compensation, a common characteristic of high-growth technology firms. The positive guidance for Q3 and full year 2025 further reinforces a strong growth trajectory and improving financial health. This performance indicates a company successfully scaling its innovative solution, making it a compelling investment opportunity for long-term growth.

Keywords

Hinge Health, Digital Health, Musculoskeletal Care, AI-powered healthcare, Telehealth, Health Technology, Q2 Earnings, Financial Results, SEC Filing, HNGE